-Andrew Tasker Researcher Activity Profile

Research Author Detailed Information 

Andrew Tasker Publication Rate By Year

Andrew Tasker has published 1 paper(s) in 1997, 1 paper(s) in 2006, 3 paper(s) in 2007, 4 paper(s) in 2008, for a total of 9 research publications in total.

Andrew A Tasker Author Information

LAST NAME: tasker

FIRST NAME: Andrew

INITIALS: a

AFFILIATION:

Papers

Andrew Tasker's Publication Record

1. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Year Published: 2006
Department of Oncology Research, Amgen, Inc., Thousand Oaks, CA 91320-1799, USA. tonyp@amgen.com
2. Review of venous thromboembolism associated with air travel. Year Published: 2007
Vascular Diseases Research Group, Academic Department of Surgery, King's Denmark Hill Campus, Bessemer Road, London SE5 9PJ, UK.
3. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
4. Theatre shoes - a link in the common pathway of postoperative wound infection? Year Published: 2008
Department of Trauma and Orthopaedics, Musgrove Park Hospital, Taunton, UK.
5. Theatre shoes - a link in the common pathway of postoperative wound infection? Year Published: 2008
Department of Trauma and Orthopaedics, Musgrove Park Hospital, Taunton, UK. ramirfeyz@yahoo.com
6. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations. Year Published: 2008
Departments of Molecular Structure, Oncology Research, Pathology, and Medicinal Chemistry, Amgen Inc., Thousand Oaks, California 91320.
7. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
8. MRI after operative reduction for developmental dysplasia of the hip. Year Published: 1997
Nuffield Orthopaedic Centre, Oxford, England, UK.
9. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. Year Published: 2008
Department of Molecular Structure, Amgen Inc., Thousand Oaks, CA 91320, USA.